Journal of Open Innovation: Technology, Market, and Complexity

Table 11 Distribution of the development phase in the anticancer (antineoplastics) dataset

From: Valuations using royalty data in the life sciences area—focused on anticancer and cardiovascular therapies

Development phase	No. of hit	%
in vitro activity	4	5.56
Preclinical	9	12.50
Phase I	11	15.28
Phase I/II	10	13.89
Phase II	19	26.39
Phase II/III	2	2.78
Phase III	14	19.44
NDA/BLA	3	4.17
Total deal number	72	100.00

Back to article page